Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; Clinical and translational results from the EORTC trial 10902

Breast Cancer Research and Treatment

Volumn 115, Issue 1, 2009, Pages 101-113

  Van Nes, Johanna G H ^a   Putter, Hein ^a   Julien, Jean Pierre ^b   Tubiana Hulin, Michelle ^c   Van De Vijver, Marc ^d   Bogaerts, Jan ^e   De Vos, Monika ^e   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE HENRI BECQUEREL   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Breast conserving surgery; EORTC; Postoperative chemotherapy; Preoperative chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67349154995     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0050-1     Document Type: Article

References (39)

1. JH Goldie AJ Coldman 1979 A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 63 1727 1733
2. B Fisher N Gunduz EA Saffer 1983 Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases Cancer Res 43 1488 1492
3. N Gunduz B Fisher EA Saffer 1979 Effect of surgical removal on the growth and kinetics of residual tumor Cancer Res 39 3861 3865
4. B Fisher N Gunduz J Coyle 1989 Presence of a growth-stimulating factor in serum following primary tumor removal in mice Cancer Res 49 1996 2001
5. B Fisher E Saffer C Rudock 1989 Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice Cancer Res 49 2002 2004
6. P Broet SM Scholl A de la Rochefordière 1999 Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial Breast Cancer Res Treat 58 151 156
7. SJ Cleator A Makris SE Ashley 2005 Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival Ann Oncol 16 267 272
8. L Mauriac G MacGrogan A Avril 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 47 52
9. JA van der Hage CJH van de Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
10. N Wolmark J Wang E Mamounas 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102
11. HD Bear S Anderson A Brown 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174
12. P Rastogi SJ Anderson HD Bear 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785
13. Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev:CD005002
14. JSD Mieog JA van der Hage MJ van de Vijver CJH van de Velde 2006 Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression Eur J Cancer 42 1369 1379
15. JL Hayward PP Carbone JC Heusen 1977 Assessment of response to therapy in advanced breast cancer Br J Cancer 35 292 298
16. H Putter M Fiocco RB Geskus 2007 Tutorial in biostatistics: competing risks and multi-state models Stat Med 26 2389 2430
17. Altman DG, Machin D, Bryant TN, Gardner MJ (2000) Statistics with confidence. British Medical Journal Books, Bristol
18. F Peintinger WF Symmans AM Gonzalez-Angulo 2006 The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 107 1248 1254
19. AM Chen F Meric-Bernstam KK Hunt 2005 Breast conservation after neoadjuvant chemotherapy Cancer 103 689 695
20. AM Chen F Meric-Bernstam KK Hunt 2004 Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience J Clin Oncol 22 2303 2312
21. EH Huang EA Strom GH Perkins 2006 Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score Int J Radiat Oncol Biol Phys 66 352 357
22. RJ Gray C Salud K Nguyen 2001 Randomized prospective evaluation of a novel technique for biopsy or lumpectomy of nonpalpable breast lesions: radioactive seed versus wire localization Ann Surg Oncol 8 711 715
23. JL Jones K Zabicki RL Christian 2005 A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important Am J Surg 190 517 520
24. EA Newman MS Sabel AV Nees 2007 Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation Ann Surg Oncol 14 2946 2952
25. Y Xing M Foy DD Cox 2006 Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer Br J Surg 93 539 546
26. T Kim AE Giuliano GH Lyman 2006 Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis Cancer 106 4 16
27. TA Buchholz CD Lehman JR Harris 2008 Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference J Clin Oncol 26 791 797
28. L Gianni M Zambetti K Clark 2005 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 7265 7277
29. J Hannemann HM Oosterkamp CA Bosch 2005 Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 23 3331 3342
30. M Colleoni G Viale D Zahrieh 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628
31. M Tubiana-Hulin D Stevens S Lasry 2006 Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution Ann Oncol 17 1228 1233
32. AE Ring IE Smith S Ashley 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017
33. V Guarneri K Broglio SW Kau 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044
34. VF Semiglazov VV Semiglazov GA Dashyan 2007 Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244 254
35. S Chua IE Smith RP A'Hern 2005 Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) Ann Oncol 16 1435 1441
36. P Therasse L Mauriac M Welnicka-Jaskiewicz 2003 Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study J Clin Oncol 21 843 850
37. G von Minckwitz G Raab A Caputo 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685
38. S Loibl G von Minckwitz G Raab 2006 Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial Ann Surg Oncol 13 1434 1442
39. IE Smith RP A'Hern GA Coombes 2004 A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial Ann Oncol: 15 751 758